A Pilot Trial of a WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation

Trial Profile

A Pilot Trial of a WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Galinpepimut S (Primary) ; Montanide ISA-51; Sargramostim
  • Indications Multiple myeloma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 16 Apr 2018 According to a SELLAS Life Sciences Group media release, results from this study was presented at European Society for Blood and Marrow Transplantation (EBMT) 44th Annual Meeting 2018.
    • 24 Jan 2018 According to a SELLAS Life Sciences Group media release, complete results from this study will be presented at European Society for Blood and Marrow Transplantation (EBMT) 44th Annual Meeting 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top